Keyword Analysis & Research: ticagrelor cas
Keyword Research: People who searched ticagrelor cas also searched
Search Results related to ticagrelor cas on Search Engine
Ticagrelor | C23H28F2N6O4S - PubChem
Ticagrelor is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes.
DA: 53 PA: 34 MOZ Rank: 76
Ticagrelor | CAS#:274693-27-5 | Chemsrc
Jan 24, 2021 · Chemsrc provides Ticagrelor(CAS#:274693-27-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Ticagrelor are included as well.
DA: 94 PA: 87 MOZ Rank: 22
Ticagrelor - CAS Common Chemistry
Ticagrelor. CAS Registry Number ... Other Names and Identifiers. CAS Common Chemistry is provided under the Creative Commons Attribution-NonCommercial 4.0 International License, or CC BY-NC 4.0 license. By using CAS …
DA: 74 PA: 12 MOZ Rank: 8
Ticagrelor ≥98% (HPLC) | 274693-27-5
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize …
DA: 57 PA: 36 MOZ Rank: 66
Ticagrelor | CAS:274693-27-5 | P2Y12 receptor antagonist ...
Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.In Vitro:Ticagrelor promotes a greater inhibition of adenosine 5′-diphosphate …
DA: 80 PA: 60 MOZ Rank: 8
What is the mechanism of action of ticagrelor?
The mechanism of action of ticagrelor is as a Phenylalanine Hydroxylase Activator, and P2Y12 Receptor Antagonist, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 3A5 Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of ticagrelor is by means of Decreased Platelet Aggregation.
DA: 43 PA: 61 MOZ Rank: 83
How is ticagrelor used in the treatment of ACS?
IDENTIFICATION AND USE: Ticagrelor is a crystalline powder. As the drug Brilinta, it is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
DA: 26 PA: 11 MOZ Rank: 91
When was ticagrelor approved for use in Europe?
Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
DA: 89 PA: 52 MOZ Rank: 76
When to use ticagrelor in high risk patients?
Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
DA: 47 PA: 62 MOZ Rank: 81